NCT04896632 - Study of Safety, Tolerability, and Pharmacokinetics of INE963 in Healthy Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 13, 2021

Primary Completion Date

November 24, 2022

Study Completion Date

November 24, 2022

Conditions

Healthy Volunteers

Interventions

DRUG

INE 963

Part A: Single ascending dose with 7 planned cohorts\> Part B: multiple dose with 2 planned cohort q24x3 days

OTHER

Placebo

Part A: single ascending dose with 7 planned cohorts. Part B: multiple dose with 2 planned q24x3 days.

Trial Locations (1)

Novartis Investigative Site, Mere Way